Jos Jansen

1 Introduction to hepatic congenital glycosylation disorders 23 20. Jaeken J. Familial psychomotor retardation with markedly fluctuating serum prolactin, FSH and GH levels, partial TBG-deficiency, increased serum arylsulphatase A and increased CSF protein: a new syndromequest;: 90. Pediatric research. 1980;14(2):179. 21. Haeuptle MA, Hennet T. Congenital disorders of glycosylation: an update on defects affecting the biosynthesis of dolichol-linked oligosaccharides. Human mutation. 2009;30(12):1628-41. 22. Freeze HH, Chong JX, Bamshad MJ, Ng BG. Solving glycosylation disorders: fundamental approaches reveal complicated pathways. American journal of human genetics. 2014;94(2):161- 75. 23. Guillard M, Morava E, de Ruijter J, Roscioli T, Penzien J, van den Heuvel L, et al. B4GALT1- congenital disorders of glycosylation presents as a non-neurologic glycosylation disorder with hepatointestinal involvement. The Journal of pediatrics. 2011;159(6):1041-3 e2. 24. Fisher P, Ungar D. Bridging the Gap between Glycosylation and Vesicle Traffic. Frontiers in cell and developmental biology. 2016;4:15. 25. Foulquier F, Amyere M, Jaeken J, Zeevaert R, Schollen E, Race V, et al. TMEM165 deficiency causes a congenital disorder of glycosylation. American journal of human genetics. 2012;91(1):15-26. 26. Kornak U, Reynders E, Dimopoulou A, van Reeuwijk J, Fischer B, Rajab A, et al. Impaired glycosylation and cutis laxa caused by mutations in the vesicular H+-ATPase subunit ATP6V0A2. Nature genetics. 2008;40(1):32-4. 27. Jaeken J. Congenital disorders of glycosylation (CDG): it’s (nearly) all in it! Journal of inherited metabolic disease. 2011;34(4):853-8. 28. Janssen MJ, Waanders E, Woudenberg J, Lefeber DJ, Drenth JP. Congenital disorders of glycosylation in hepatology: the example of polycystic liver disease. Journal of hepatology. 2010;52(3):432-40. 29. Pelletier VA, Galeano N, Brochu P, Morin CL, Weber AM, Roy CC. Secretory diarrhea with protein- losing enteropathy, enterocolitis cystica superficialis, intestinal lymphangiectasia, and congenital hepatic fibrosis: a new syndrome. The Journal of pediatrics. 1986;108(1):61-5. 30. Blomme B, Van Steenkiste C, Callewaert N, Van Vlierberghe H. Alteration of protein glycosylation in liver diseases. Journal of hepatology. 2009;50(3):592-603. 31. Rao MN, Lakshman MR. Chronic ethanol consumption leads to destabilization of rat liver beta-galactoside alpha2,6-sialyltransferase mRNA. Metabolism: clinical and experimental. 1999;48(6):797-803. 32. Gong M, Garige M, Hirsch K, Lakshman MR. Liver Galbeta1,4GlcNAc alpha2,6-sialyltransferase is down-regulated in human alcoholics: possible cause for the appearance of asialoconjugates. Metabolism: clinical and experimental. 2007;56(9):1241-7. 33. Mehta A, Block TM. Fucosylated glycoproteins as markers of liver disease. Disease markers. 2008;25(4-5):259-65. 34. Noda K, Miyoshi E, Uozumi N, Yanagidani S, Ikeda Y, Gao C, et al. Gene expression of alpha1-6 fucosyltransferase in human hepatoma tissues: a possible implication for increased fucosylation of alpha-fetoprotein. Hepatology. 1998;28(4):944-52. 35. Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology. 1995;22(3):802-7. 36. Taketa K, Sekiya C, Namiki M, Akamatsu K, Ohta Y, Endo Y, et al. Lectin-reactive profiles of alpha- fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology. 1990;99(2):508-18. 37. Adam R, Karam V, Cailliez V, JG OG, Mirza D, Cherqui D, et al. 2018 Annual Report of the